In the rat model of COPD treated with resveratrol, serum IL-6 and IL-8 levels were decreased and lung inflammation was inhibited.150 In addition, resveratrol activation of SIRT1 also downregulates the activity of MMP9 in fibroblasts in COPD.151 In recent years, it has been found that SRT1720 is a compound that can activate SIRT1, which can improve lung function and reduce lung damage caused by CS152 (Table 1). The gene discussed is SIRT1; the disease is chronic obstructive pulmonary disease.